

NCT03380429 Raw comparison:

Summary:
CHIA has 22 criteria while your personal folder has 24 criteria
Total found criteria: 22/22
Total not Found: 0/22
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Subjects aged 18 years or older at the time of     │ Subjects aged 18 years or older at the time of     │
│ signing the informed consent                       │ signing the informed consent                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with documented physician diagnosis of    │ Subjects with documented physician diagnosis of    │
│ asthma as their primary respiratory disease        │ asthma as their primary respiratory disease        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ ACT score <20 at screening visit                   │ ACT score \<20 at screening visit                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Non-smokers (never smoked or not smoking for >6    │ Non-smokers (never smoked or not smoking for \>6   │
│ months with <10 pack years history (Pack years =   │ months with \<10 pack years history (Pack years =  │
│ [cigarettes per day smoked/20] multiplied by       │ \[cigarettes per day smoked/20\] multiplied by     │
│ number of years smoked)                            │ number of years smoked)                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or female subjects will be included A female  │ Male or female subjects will be included A female  │
│ subject is eligible to participate if she is not   │ subject is eligible to participate if she is not   │
│ pregnant not breastfeeding and at least one of the │ pregnant not breastfeeding and at least one of the │
│ following conditions applies (i) Not a woman of    │ following conditions applies (i) Not a woman of    │
│ childbearing potential (WOCBP) (ii) A WOCBP who    │ childbearing potential (WOCBP) (ii) A WOCBP who    │
│ agrees to follow the contraceptive guidance during │ agrees to follow the contraceptive guidance during │
│ the treatment period and for at least 5 days]      │ the treatment period and for at least 5 days\]     │
│ after the last dose of study treatment             │ after the last dose of study treatment             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Capable of giving signed informed consent which    │ Capable of giving signed informed consent which    │
│ includes compliance with the requirements and      │ includes compliance with the requirements and      │
│ restrictions listed in the consent form and        │ restrictions listed in the consent form and        │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject understands and is willing able and likely │ Subject understands and is willing able and likely │
│ to comply with study procedures and restrictions   │ to comply with study procedures and restrictions   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject must be able to read in a language         │ Subject must be able to read in a language         │
│ supported by the smart phone app in their region   │ supported by the smart phone app in their region   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject must have been on maintenance therapy      │ Subject must have been on maintenance therapy      │
│ (Fixed dose combination ICS/LABA) for 3 months     │ (Fixed dose combination ICS/LABA) for 3 months     │
│ cannot have changed dose in the month prior to     │ cannot have changed dose in the month prior to     │
│ screening and be able to change to an equivalent   │ screening and be able to change to an equivalent   │
│ dose of RELVAR/BREO for the duration of the study  │ dose of RELVAR/BREO for the duration of the study  │
│ Other background asthma medication such as anti-   │ Other background asthma medication such as anti-   │
│ leukotrienes and oral corticosteroids are          │ leukotrienes and oral corticosteroids are          │
│ permitted provided the dose has been stable for 1  │ permitted provided the dose has been stable for 1  │
│ month prior to screening                           │ month prior to screening                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject must be able to change to                  │ Subject must be able to change to                  │
│ Salbutamol/Albuterol MDI rescue for the duration   │ Salbutamol/Albuterol MDI rescue for the duration   │
│ of the study and judged capable of withholding     │ of the study and judged capable of withholding     │
│ albuterol/salbutamol for at least 6 hours prior to │ albuterol/salbutamol for at least 6 hours prior to │
│ study visits                                       │ study visits                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject must have their own Android or iPhone      │ Subject must have their own Android or iPhone      │
│ operating system (IOS) smart phone and a data      │ operating system (IOS) smart phone and a data      │
│ package suitable for the installation and running  │ package suitable for the installation and running  │
│ of the app and sending and receiving data Data     │ of the app and sending and receiving data Data     │
│ used by the CIS is approximately 1 megabyte (MB)   │ used by the CIS is approximately 1 megabyte (MB)   │
│ per month as a maximum this is less data than a 1  │ per month as a maximum this is less data than a 1  │
│ minute video streamed from YouTube (2MB)           │ minute video streamed from YouTube (2MB)           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects must be willing and able to download the  │ Subjects must be willing and able to download the  │
│ app on their personal smart phone and keep it      │ app on their personal smart phone and keep it      │
│ turned on for the duration of the study This will  │ turned on for the duration of the study This will  │
│ also require Bluetooth to be turned on for         │ also require Bluetooth to be turned on for         │
│ duration of the study Subjects will also have to   │ duration of the study Subjects will also have to   │
│ turn on mobile data for the app for the duration   │ turn on mobile data for the app for the duration   │
│ of study unless travelling and when extra data     │ of study unless travelling and when extra data     │
│ roaming costs could be incurred                    │ roaming costs could be incurred                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ ACT score <20 at randomization visit (visit 2)     │ ACT score \<20 at randomization visit (visit 2)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with a known or suspected alcohol or drug │ Subjects with a known or suspected alcohol or drug │
│ abuse which in the opinion of the investigator     │ abuse which in the opinion of the investigator     │
│ could interfere with the subject's proper          │ could interfere with the subject's proper          │
│ completion of the protocol requirement             │ completion of the protocol requirement             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of life threatening asthma Defined as an   │ History of life threatening asthma Defined as an   │
│ asthma episode that required intubation and/or was │ asthma episode that required intubation and/or was │
│ associated with hypercapnea respiratory arrest or  │ associated with hypercapnea respiratory arrest or  │
│ hypoxic seizures within the last 6 months          │ hypoxic seizures within the last 6 months          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A lower respiratory tract infection within 7 days  │ A lower respiratory tract infection within 7 days  │
│ of the screening visit                             │ of the screening visit                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent diagnosis of chronic obstructive        │ Concurrent diagnosis of chronic obstructive        │
│ pulmonary disease (COPD) or other respiratory      │ pulmonary disease (COPD) or other respiratory      │
│ disorders including active tuberculosis lung       │ disorders including active tuberculosis lung       │
│ cancer bronchiectasis sarcoidosis lung fibrosis    │ cancer bronchiectasis sarcoidosis lung fibrosis    │
│ pulmonary hypertension interstitial lung diseases  │ pulmonary hypertension interstitial lung diseases  │
│ or other active pulmonary diseases                 │ or other active pulmonary diseases                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypersensitivity/intolerance to any     │ History of hypersensitivity/intolerance to any     │
│ components of the study inhalers (example lactose  │ components of the study inhalers (example lactose  │
│ magnesium stearate) In addition subjects with a    │ magnesium stearate) In addition subjects with a    │
│ history of severe milk protein allergy that in the │ history of severe milk protein allergy that in the │
│ opinion of the study physician contraindicates     │ opinion of the study physician contraindicates     │
│ participation will also be excluded                │ participation will also be excluded                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Historical or current evidence of clinically       │ Historical or current evidence of clinically       │
│ significant or rapidly progressing or unstable     │ significant or rapidly progressing or unstable     │
│ cardiovascular neurological cardiovascular         │ cardiovascular neurological cardiovascular         │
│ neurological renal hepatic immunological endocrine │ neurological renal hepatic immunological endocrine │
│ (including uncontrolled diabetes or thyroid        │ (including uncontrolled diabetes or thyroid        │
│ disease) or hematological abnormalities that are   │ disease) or hematological abnormalities that are   │
│ uncontrolled Significant is defined as any disease │ uncontrolled Significant is defined as any disease │
│ that in the opinion of the investigator would put  │ that in the opinion of the investigator would put  │
│ the safety of the subject at risk through          │ the safety of the subject at risk through          │
│ participation or which would affect the analysis   │ participation or which would affect the analysis   │
│ if the disease/condition exacerbated during the    │ if the disease/condition exacerbated during the    │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have ever received treatment with     │ Subjects who have ever received treatment with     │
│ biological based therapy example omalizumab        │ biological based therapy example omalizumab        │
│ mepolizumab for asthma                             │ mepolizumab for asthma                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have received an investigational drug │ Subjects who have received an investigational drug │
│ and/or medical device within 30 days of entry into │ and/or medical device within 30 days of entry into │
│ this study (Screening) or within five drug half-   │ this study (Screening) or within five drug half-   │
│ lives of the investigational drug whichever is     │ lives of the investigational drug whichever is     │
│ longer                                             │ longer                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A subject will not be eligible for this study if   │ A subject will not be eligible for this study if   │
│ he/she is an immediate family member of the        │ he/she is an immediate family member of the        │
│ participating investigator sub-investigator study  │ participating investigator sub-investigator study  │
│ coordinator employee of the participating          │ coordinator employee of the participating          │
│ investigator or any family member of a Propeller   │ investigator or any family member of a Propeller   │
│ Health employee                                    │ Health employee                                    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒══════════════════════════════════════╕
│ Extra Personal Criteria              │
╞══════════════════════════════════════╡
│ Inclusion criteria for randomization │
├──────────────────────────────────────┤
│ Must have minimum age of 18 Years    │
╘══════════════════════════════════════╛